Salivary Gland Cancer Clinical Trial
Official title:
Prognostic Factors for Survival of Patients With Salivary Gland Malignancies
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival
The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03729297 -
Cabozantinib in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT01969578 -
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT01703455 -
Activity of Sorafenib in Salivary Gland Cancer
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03781986 -
APG-115 in Salivary Gland Cancer Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05483374 -
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
|
||
Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03172624 -
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT00509002 -
Iressa Study in Patients With Salivary Gland Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05008237 -
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
|
Phase 2 | |
Recruiting |
NCT03360890 -
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05898373 -
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Completed |
NCT01344356 -
Stereotactic Body Radiotherapy for Head and Neck Tumors
|
Phase 4 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 |